Latest GlaxoSmithKline Stories
LONDON, April 30, 2014 /PRNewswire/ -- GlaxoSmithKline plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved Incruse(TM) Ellipta(®) (umeclidinium)
LONDON, April 30, 2014 /PRNewswire/ -- SOURCE GlaxoSmithKline
LONDON, April 29, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:
RESEARCH TRIANGLE PARK, N.C. and SOUTH SAN FRANCISCO, Calif., April 28, 2014 /PRNewswire/ -- GlaxoSmithKline plc (LSE/NYSE: GSK) and Theravance, Inc.
Healthcare market research firm Kalorama Information says the pharmaceutical giant Novartis benefits a bit more from its recently announced partnership with Glaxo Smith Kline. New
PARSIPPANY, N.J., April 24, 2014 /PRNewswire/ -- The U.S.
Analysis points to three potential blockbusters: Sovaldi, Anoro Ellipta and Idelalisib entering market this year PHILADELPHIA, April 16, 2014 /PRNewswire/ -- The
OXFORD, England and PITTSBURGH, April 15, 2014 /PRNewswire/ -- Prosonix, an innovative speciality pharmaceutical company developing a portfolio of inhaled Respiratory Medicines by Design,
LONDON, April 14, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:
Tamiflu is widely used to help patients relieve symptoms of influenza. While the drug – generically known as oseltamivir – can shorten symptoms by about half a day, there is no good evidence to support claims that it reduces admissions to the ER or complications of influenza.
- totally perplexed and mixed up.